Teva discontinues Phase 2 study of Emrusolmin in multiple system atrophy

What happened

Teva said it will discontinue the Phase 2 TOPAS-MSA study of emrusolmin in adults with multiple system atrophy after an independent committee found a low probability of meeting the study’s main effectiveness goal. The interim review found no safety concerns; Teva says the decision is not final for the drug’s wider development program.

Confirmed

Global impact / market context

Stopping this study removes a near-term route for generating evidence that could support emrusolmin’s development in multiple system atrophy. Teva’s planned review of the study and extension data could shape whether it invests further in the program, while the article reports no final decision on broader development.

Analyst inference

The article reports Teva shares fell 3.6% before the market opened, to $40.7. The study result is a setback for this particular development effort, but the interim assessment predicts a low chance of success rather than providing the final efficacy analysis or ending the wider program.

Confirmed

What to watch

1. Teva plans a comprehensive analysis of TOPAS-MSA data and available open-label extension data, a follow-up study where participants may continue treatment without a comparison group. Confirmed
2. The company plans to share TOPAS-MSA findings with the scientific community after its comprehensive analysis is completed. Confirmed
3. Whether Teva continues emrusolmin development will depend partly on what the full data review shows; the article says the study closure is not a final program decision. Analyst inference

Evidence

• seekingalpha.com